GRIN Therapeutics, Inc.

This #PatientAccessWeek, we recognize the importance of access. In neurodevelopmental disorders, clinical trial processes can be complex. We remain committed to providing access to advocacy resources and clinical trial information: grintherapeutics.com/resources-for-…

Autism can be a feature of several rare neurodevelopmental conditions, and recognizing these conditions helps drive support, awareness, and inclusion. Learn more at @autismspeaks: autismspeaks.org/world-autism-a… #WorldAutismDay

This #PurpleDay, we recognize the resilience of those affected by epilepsy and renew our commitment to research that looks beyond seizures, helping to bring hope and better solutions to the broader community.

From March 12–18, we join the GRIN community in recognizing GRIN2B Awareness Week. Visit @GRIN2Bsyndrome's to explore resources and learn more about this growing community: grin2b.com/common-questio…

Recently, the @AmerAcadPeds updated its guidelines for evaluating children with intellectual disability (ID) or global developmental delay (GDD), Learn more from AAP: publications.aap.org/aapnews/news/3…

During Medical Genetics Awareness Week, we recognize the critical role of genetic testing in diagnosing rare neurodevelopmental disorders.

Patient safety is at the heart of everything we do at GRIN Therapeutics. This #PatientSafetyAwarenessWeek, we are proud to honor the trust families place in us and remain focused on advancing research while keeping safety at the forefront of every study.

This month is GRI Disorders Awareness Month —a time to honor the patients, families, clinicians, and researchers who make up the GRIN community.

Hosted by the @NACDD, #DevelopmentalDisabilitiesAwarenessMonth highlights the importance of people with disabilities and the communities that support them. As we advance investigational radiprodil, we are committed to deepening understanding across the community.

#RDD2026 is a moment to listen, to learn, and to recommit—to the families who drive our work, to the advocates who raise their voices, and to the researchers and clinicians pushing science forward. #MoreThanYouCanImagine

On #RareDiseaseDay, we join @EURORDIS and @NORD in recognizing children and families living every day with rare neurological disorders.

Momentum in rare, genetically defined neurodevelopmental diseases continues to shape the neuroscience outlook for 2026. Our CEO Bruce Leuchter, M.D., shares why in this @PharmExec interview: pharmexec.com/view/trends-ne…

On #NationalCaregiversDay, we celebrate and thank every caregiver whose love, dedication, and advocacy empower patients and communities. It is an honor to witness your commitment, amplify your voices, and support you in making a meaningful difference.

Today is #InternationalEpilepsyDay, an initiative led by the @IBESocialMedia and the @IlaeWeb to raise #epilepsy awareness. A reminder of the importance of understanding the biological mechanisms behind these conditions & advancing research that can make a meaningful difference.

During #PatientRecognitionWeek, we want to take a moment to thank the patients and families whose resilience and dedication continue to ground our work at GRIN Therapeutics every day

We extend our gratitude to the principal investigators, scientific key opinion leaders, the patient community, clinical and regulatory stakeholders, and our partner @AngeliniPharma for their extensive collaboration. Learn more in our press release: prnewswire.com/news-releases/…

We’re proud to announce that we have dosed the first patient in the global Phase 3 Beeline trial of our investigational therapy, radiprodil, in GRIN-related neurodevelopmental disorder (GRIN-NDD).

As we celebrate the holidays, we want to express our gratitude to our team, partners, and the patient advocacy community. Your support has been crucial to our progress, and we’re excited to continue building on this momentum together in the year ahead.

Attending #AES2025 was a meaningful way to close out the year and reflect on the strides we’ve made in advancing research. We are grateful for the meaningful conversations and renewed momentum as we continue our mission to develop impactful treatments.

We recently teamed up with the @GRIN2Bsyndrome and @CureGRIN for a webinar as part of their Clinical Trials Series. Watch here to learn about our global Phase 3 Beeline trial and our precision approach to GRIN-NDD: youtube.com/watch?v=VJw-Ik…